Back to results
US 2013/0210730 A1Published application
Method of treating dyspnea associated with acute heart failure
AssigneeNovartis AG
InventorsElaine Unemori, Sam L. Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
Life of this patent
Estimating the term…
Abstract
The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
Claims21
1-75. (canceled)
77:
- The method of claim 76 wherein fewer deaths occur by day 180 in subjects who receive relaxin than those who receive a placebo.
78:
- A method of lowering all-cause mortality in a hypertensive or normotensive human subject with acute heart failure comprising administering a therapeutically effective amount of a pharmaceutically active H2 relaxin to the subject.
78:
- The method of claim 77 wherein fewer deaths occur by day 135 in subjects who receive relaxin than those who receive a placebo.
79:
- The method of claim 76 wherein fewer deaths occur by day 90 in subjects who receive relaxin than those who receive a placebo.
80:
- The method of claim 79 wherein fewer deaths occur by day 45 in subjects who receive relaxin than those who receive a placebo.
81:
- The method of claim 80 wherein fewer deaths occur by day 30 in subjects who receive relaxin than those who receive a placebo.
82:
- The method of claim 81 wherein fewer deaths occur by day 14 in subjects who receive relaxin than those who receive a placebo.
83:
- The method of claim 76 wherein the hazard ratio is less than or equal to about 0.70.
84:
- The method of claim 83 wherein the hazard ratio is less than or equal to about 0.60.
85:
- The method of claim 84 wherein the hazard ratio is less than or equal to about 0.50.
86:
- A method of reducing death from cardiovascular causes in a hypertensive or normotensive human subject with acute heart failure comprising administering a therapeutically effective amount of a pharmaceutically active H2 relaxin to the subject.
87:
- The method of claim 86 wherein fewer deaths from cardiovascular causes occur by day 180 in subjects administered relaxin than in subjects administered placebo.
88:
- The method of claim 87 wherein fewer deaths from cardiovascular causes occur by day 60 in subjects administered relaxin than in subjects administered placebo.
89:
- The method of claim 88 wherein fewer deaths from cardiovascular causes occur by day 30 in subjects administered relaxin than in subjects administered placebo.
90:
- A method of reducing renal impairment in a hypertensive or normotensive human subject with acute heart failure comprising administering a therapeutically effective amount of a pharmaceutically active H2 relaxin to the subject.
91:
- The method of claim 90 wherein the incidence of renal impairment is reduced to less than or equal to about 5%.
92:
- The method of claim 90 wherein the renal impairment comprises renal failure.
93:
- The method of claim 90 wherein the renal impairment comprises a rise in serum creatinine.
94:
- The method of claim 93 wherein the serum creatinine level on day five is lower in subjects who were administered relaxin than in subjects who were administered a placebo.
95:
- The method of claim 93 wherein serum creatinine increases of more than about 0.5 mg/dl occur in fewer subjects who were administered relaxin than in subjects who were administered a placebo.